Literature DB >> 23242099

Naltrexone-induced Nicolau syndrome masquerading as cutaneous abscess.

Daniel Perli1, Catharine Martone, Alwyn Rapose.   

Abstract

Nicolau syndrome-also known as Embolia Cutis Medicamentosa-is a rare complication of intramuscular and subcutaneous injections manifesting as necrosis of skin and the underlying tissues. The exact pathogenesis is uncertain. There are several hypotheses including direct damage to the end artery, cytotoxic effects of the implicated drug or additives in the injectable preparations. Naltrexone is a long-acting opioid antagonist used primarily in the management of alcohol and opioid dependence. The patient received intramuscular naltrexone for treatment of alcoholism. A week later, she presented with what appeared to be cellulitis at the site of injection. It progressed in spite of antibiotics and mimicked an abscess. Attempted incision and drainage however yielded no pus. Deep tissue necrosis was seen and histopathology was consistent with Nicolau syndrome. As per our knowledge, this is the first reported case of naltrexone associated Nicolau syndrome that masqueraded as a buttock abscess.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242099      PMCID: PMC4544998          DOI: 10.1136/bcr-2012-007785

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Three cases of embolia cutis medicamentosa (Nicolau's syndrome).

Authors:  Giovanni Francesco Marangi; Pierluigi Gigliofiorito; Vito Toto; Marika Langella; Tiziano Pallara; Paolo Persichetti
Journal:  J Dermatol       Date:  2010-05       Impact factor: 4.005

2.  Plasma concentrations during naltrexone implant treatment of opiate-dependent patients.

Authors:  Linda Olsen; Asbjørg S Christophersen; Grete Frogopsahl; Helge Waal; Jørg Mørland
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

3.  Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.

Authors:  James C Garbutt; Henry R Kranzler; Stephanie S O'Malley; David R Gastfriend; Helen M Pettinati; Bernard L Silverman; John W Loewy; Elliot W Ehrich
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

4.  Nicolau syndrome following etanercept administration.

Authors:  Claudio Guarneri; Giovanni Polimeni
Journal:  Am J Clin Dermatol       Date:  2010       Impact factor: 7.403

Review 5.  Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics.

Authors:  Lara A Ray; Pauline F Chin; Karen Miotto
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-03       Impact factor: 4.388

Review 6.  Nicolau Syndrome: three cases and review.

Authors:  Kelli Luton; Carlos Garcia; Eduardo Poletti; Glen Koester
Journal:  Int J Dermatol       Date:  2006-11       Impact factor: 2.736

Review 7.  [Nicolau syndrome caused by penicillin preparations: review of the literature in search for potential risk factors].

Authors:  V Saputo; G Bruni
Journal:  Pediatr Med Chir       Date:  1998 Mar-Apr

8.  Nicolau syndrome induced by intramuscular vitamin K in a premature newborn.

Authors:  Esad Koklu; Serdar Umit Sarici; Demet Altun; Omer Erdeve
Journal:  Eur J Pediatr       Date:  2009-03-11       Impact factor: 3.183

9.  Naltrexone in the treatment of alcohol dependence.

Authors:  J R Volpicelli; A I Alterman; M Hayashida; C P O'Brien
Journal:  Arch Gen Psychiatry       Date:  1992-11

10.  A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence.

Authors:  Bankole A Johnson; Nassima Ait-Daoud; Henri-Jean Aubin; Wim Van Den Brink; Richard Guzzetta; John Loewy; Bernard Silverman; Elliot Ehrich
Journal:  Alcohol Clin Exp Res       Date:  2004-09       Impact factor: 3.455

View more
  1 in total

1.  Crushed and injected buprenorphine tablets: characteristics of princeps and generic solutions.

Authors:  Régis Bouquié; Laura Wainstein; Paul Pilet; Jean-Marie Mussini; Guillaume Deslandes; Johann Clouet; Eric Dailly; Pascale Jolliet; Caroline Victorri-Vigneau
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.